Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission.
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been applied to patients with diffuse large Bcell lymphoma (DLBCL); it is well established that ASCT shows significant survival benefits for chemosensitive relapse. However, half of relapsed patients are resistant to salvage chemotherapy, indicating that they are not suitable for ASCT. We retrospectively analyzed the clinical records of 47 patients with DLBCL classified as high or high-intermediate (higher) risk, according to the International Prognostic Index, who underwent upfront ASCT in first complete remission (CR1). Compared with 10 patients with similar characteristics who did not receive ASCT, event free survival at 5-year was significantly superior in ASCT group. Toxicity of ASCT was acceptable and therapy-related death was not observed. We therefore propose that upfront ASCT for higher risk DLBCL in CR1 might provide survival benefit, probably because the high-dose therapy removes minimally resided tumor.
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital , Japan.
Hiroto
H
Kaneko
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital , Japan.
Yasuhiko
Y
Tsutsumi
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital , Japan.
Takahiro
T
Fujino
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital , Japan.
Saeko
S
Kuwahara
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital , Japan.
Muneo
M
Ohshiro
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital , Japan.
Toshiki
T
Iwai
Department of Hematology/Oncology, Kyoto Prefectural University of Medicine , Japan.
Junya
J
Kuroda
Department of Hematology/Oncology, Kyoto Prefectural University of Medicine , Japan.
Shouhei
S
Yokota
Department of Hematology/Oncology, Kyoto Prefectural University of Medicine , Japan.
Shigeo
S
Horiike
Department of Hematology/Oncology, Kyoto Prefectural University of Medicine , Japan.
Masafumi
M
Taniwaki
Diffuse large B-cell lymphoma; autologous transplantation; upfront